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graft occlusion
Linn Koraen, MD,a Monica Kuoppala, MD,b Stefan Acosta, MD, PhD,b and
Carl-Magnus Wahlgren, MD, PhD,a Stockholm and Malmö, Sweden
Background: Thrombolysis is a common method in the treatment of lower extremity bypass graft occlusion. The purpose
of this study was to investigate the results of thrombolytic therapy in the management of acute bypass graft occlusion and
to identify risk factors for technical failure and amputation.
Methods: All patients at two tertiary referral centers undergoing thrombolysis for acute graft occlusion in the lower limb
between January 1, 2000 and December 31, 2008 were retrospectively reviewed. Factors associated with technical failure
of thrombolytic therapy, major amputation, and mortality were determined with multivariate analysis, and long-term
outcomes were assessed with the Kaplan-Meier method and log-rank test.
Results:During the study period, 123 patients underwent thrombolysis for acute bypass graft occlusion. Mean age was 69
years (range, 27-91 years); 38% were women. Sixty-seven percent had synthetic grafts. Acute critical leg ischemia (74%)
was the dominating symptom preceding thrombolytic treatment. In 29% of cases, no adjunctive interventions were
required, whereas 21% underwent open surgery, 39% endovascular intervention, and 11% underwent a hybrid procedure.
Technical failure of thrombolysis occurred in 18 patients. Presence of ischemic heart disease (P .013), older grafts (P
.014), and synthetic grafts (trend; P  .092) were associated with success of thrombolysis, and ischemic heart disease
remained as an independent factor in the multivariate analysis for technical success of thrombolysis (P  .04; odds ratio
4.0; 95% confidence interval [CI; 1.1-15.1]), whereas there was a trend for older grafts (P  .089). Mean follow-up was
38 months (range, 0-119 months). The major amputation rate was 11% (14/123) at 1 month and 25% (31/122) at 1
year. In a Cox regressionmodel, technical failure (P .031; hazard ratio [HR] 2.58, 95% CI [1.0-6.08]), higher age (P
.004; HR 1.06, 95% CI [1.02-1.10]), and synthetic graft as opposed to vein graft (P .050; HR 2.63, 95% CI [1.0-6.9])
remained as independent factors associated with major amputation. The amputation-free survival rate was 89% and 75%
at 1 and 12 months, respectively. Higher age (P < .001; HR 1.06, 95% CI [1.03-1.09]) and acute limb ischemia (P 
.007; HR 2.40, 95% CI [1.26-4.56]) remained as independent adverse factors associated with amputation-free survival.
Conclusions: Our findings support the use of thrombolysis in the treatment of acute bypass graft occlusion in the lower
limb given its acceptable short- and long-term amputation-free survival rates. Technical failure and higher age were
factors associated with major amputation. Synthetic grafts appeared to have a somewhat increased likelihood of
technically successful thrombolysis compared with vein grafts, but on the other hand, they exhibited an increased risk of
amputation during follow-up. (J Vasc Surg 2011;54:1339-44.)
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become increasingly prominent in the treatment of periph-
eral vascular disease both in the acute and chronic setting.
Since it was first described by Dotter in 1974,1 intra-
arterial thrombolysis has evolved as a common method in
the treatment of acute lower limb ischemia. The efficacy of
thrombolysis has been investigated in a number of stud-
ies.2,3 It has been shown to give acceptable results concern-
ing amputation-free survival, complications, and mortality
in acute arterial occlusions.4,5 However, to date there are
few studies looking specifically at the outcomes of throm-
bolysis in the treatment of graft occlusion in the lower limb.
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esults of thrombolytic therapy in the management of acute
ypass graft occlusion at our institutions and to identify risk
actors for technical failure and amputation.
ETHODS
Setting. The Karolinska University Hospital, Stock-
olm, and the Vascular Center, Malmö-Lund, are tertiary
eferral centers for vascular diseases with a combined pri-
ary catchment area of approximately 1.8 million people.
Study population. The study comprises all patients at
he two participating centers undergoing thrombolysis for
cute bypass graft occlusion in the lower limb between
anuary 1, 2000 (Karolinska), January 2001(Malmö), and
ecember 31, 2008. The patients were identified through
he hospital database of radiological procedures (Karolin-
ka) and the prospective database for endovascular inter-
entions (Malmö-Lund). Forty-four of the patients with
ccluded bypasses from Malmö in this study were also
ncluded in a previous study on 220 thrombolytic proce-
ures for all causes of lower limb ischemia.5 For inclusion
nto the study, the duration of graft occlusion had to be
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November 20111340 Koraen et al30 days, and there had to be at least one infrainguinal
anastomosis.
Local intra-arterial thrombolysis. According to lo-
cal protocol, all patients were screened for the presence of
any absolute or relative contraindications to thrombolysis.
Absolute contraindications were surgery/organ biopsy 2
weeks, cerebrovascular accident 6 weeks, cerebral metas-
tases, known cerebral arteriovenous malformation, and
placement of epidural anesthesia/other dural puncture3
days.
Prior to commencement of thrombolysis, coagulation
tests were performed. Any imaging (computer tomogra-
phy, ultrasound, magnetic resonance imaging) obtained
previously was examined before initiation of thrombolysis.
Standard arterial access was achieved through puncture of
the contralateral or ipsilateral common femoral artery in the
groin. A guidewire was passed through the occluded grafts
prior to insertion of the thrombolysis catheter, except in
cases with aortobifemoral limb occlusion, where the oper-
ator sometimes chose to place the tip of an end-hole
catheter into the most proximal part of the thrombus after
catheterization of the open contralateral limb first.
A thrombolysis catheter was then placed, after which
an infusion of alteplase (Actilyse; Boehringer Ingelheim,
Stockholm, Sweden) was commenced. The pulse-spray
method was usually performed at Karolinska, but not
in Malmö. Mechanical thrombolysis was performed as
an adjunctive procedure in two patients (Angiojet
[MEDRAD, Warrendale, Pa] and Rotarex [Straub Medi-
cal, Wangs, Switzerland], respectively.).
A dose of 1 to 2 mg/h (volume of infusate between 10
and 20mL/hwith 0.1mg alteplase/mL) was initially often
infused for 4 hours followed by a reduced dose of 0.5 to 1
mg/h depending on the extent and age of the occlusion, as
well as the degree of ischemia, patient’s age, and risk
factors. At the start of thrombolysis, 5000 units of unfrac-
tionated heparin was given intra-arterially. During the
thrombolysis, patients were given subcutaneous low-
molecular weight heparin (20 mg subcutaneously every 6
hours; Karolinska) or unfractionated heparin through the
introducer adjusted to activated partial thromboplastin
time values to a target of two to three times the reference
value (Malmö-Lund). Fibrinogen, prothrombin complex,
hemoglobin, platelet, and creatinine levels were checked
continuously according to protocol.
Angiographic controls were performed either once or
twice daily during daytime, based on the previous angio-
graphic findings, clinical status of the limb, and occurrence
of any bleeding complications.
Degrees of lysis were defined as complete, partial, lysis
but no run-off, or no lysis.6
Significant lesions were defined by the angiographic
appearance and judgment by the operator.
Patients received and continued with antiplatelet ther-
apy and lipid lowering agents post-thrombolysis. Occasion-
ally warfarin treatment was initiated, especially if there was
an occlusion of a synthetic bypass graft without an apparent
flow-limiting reason. Duplex graft surveillance was per- vormed after thrombolysis according to local protocol.
evere graft stenosis (75%) was defined as graft failure,
nd these patients were often scheduled for endovascular
ntervention. Patients with moderate graft stenosis (50%-
5%) were often followed with duplex.
Analysis of patient data. We performed a retrospec-
ive review of the records of the included patients as well as
f the radiological imaging studies related to the thrombo-
ytic treatment.
Data on mortality and amputation were collected di-
ectly from patient records or through the Swedish Popu-
ation registry.
Definitions. Hypertension was defined as a systolic
lood pressure of 140 or a diastolic blood pressure of
90 or both on at least two separate occasions. Patients
ere also classified as hypertensive if they had been previ-
usly diagnosed with hypertension (as stated in their med-
cal records) or were treated with antihypertensive medica-
ion. Cerebrovascular disease was defined as a history of
anifest stroke or transient ischemic attack. Ischemic heart
isease was defined as the presence of previous myocardial
nfarction, angina pectoris, previous coronary artery bypass
rafting, or percutaneous coronary intervention. Diabetes
ellitus was noted if the patient was either on diet treat-
ent, oral hypoglycemic agents, or insulin. Smoking was
efined as a history of either current or previous smoking.
trial fibrillation was noted if the patient had a history of
ither chronic or paroxysmal atrial fibrillation. Acute critical
schemia of the lower limb was defined as a sudden impair-
ent in limb perfusion causing a potential threat to tissue
iability in the affected limb (Rutherford class 4 and above).
he definition of acute graft occlusion included all clinical
ategories (0-6) of Rutherford classification. Technical fail-
re was defined as insufficient degree of lysis (either no lysis
r lysis without run-off on completion angiogram) and
uccess as complete or partial lysis.6
Additional interventions were defined as endovascular
stenting, percutaneous intraluminal angioplasty, aspira-
ion of thrombotic material), open (thrombectomy/embo-
ectomy, bypass grafting, graft revision, thrombendarterec-
omy, other vascular reconstruction) or hybrid (combined
ndovascular and open procedures during the same ses-
ion). Amputation was defined as any amputation above the
evel of the tarsometatarsal joint (major amputation). Ma-
or hemorrhage was defined as hemorrhage of such severity
hat intervention (surgical intervention or blood transfu-
ion) or termination of thrombolysis was required. Blood
ransfusion was undertaken based on the patient’s clinical
tatus; generally a hemoglobin value of 80 g/L was used
s a cut-off point.
Statistical methods. Data analysis was performed us-
ng SPSS, version 18.0 (IBM, New York, NY). Values were
xpressed as mean  standard deviation unless otherwise
pecified. Univariate analyses of binary, nominal, and ordi-
al variables were conducted using cross-tabulations (val-
es reported for Pearson’s 2, Fisher exact test, Cramer’s V,
nd Kendall’s tau-b test). Correlations between nominal
ariables were evaluated with the Spearman correlation
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.1) were entered into a logistic regression model with
forced entry of the variables, and significant associations
were expressed in terms of odds ratios (OR) with 95%
confidence intervals (CI). For analysis of predictors of
amputation, mortality, or amputation or mortality, vari-
ables (P .1 in the univariate analysis) were entered into a
Cox regression model (forced entry), and significant asso-
ciations were expressed in terms of hazard ratios (HR) with
95% CI. Leg and patient survival was analyzed using the
Kaplan-Meier method, and group differences were evalu-
ated with the log-rank test. Statistical significance was con-
sidered for P values of less than .05.
RESULTS
Frequency of thrombolysis. During the study pe-
riod, there were a total of 659 intra-arterial thrombolyses at
the two centers. There were 123 patients who underwent
thrombolysis for acute bypass graft occlusion of 30 days’
duration and who had at least one infrainguinal anastomo-
sis. Rethrombolysis for reocclusion of the same bypass graft
was performed in 19 (15.4%) patients twice, nine (7.3%)
patients three times, and two (1.6%) patients five times.
Fifteen (79%) out of these 19 patients had a synthetic
bypass. Median time to first rethrombosis in these 19 grafts
was six months (range, 0.3-26 months).
Patients. The mean age of the study population (n 
Table I. Factors associated with technical failure and long
occlusion in the lower limb
Patients (%)
Technical failure
(%) Ma
All 123 18 (15)
Women 47 (38) 7 (15)
Age 80 years 26 (21) 4/26 (15)
Smoking 86/107 (80) 14 (16)
Hypertension 88/122 (72) 14 (16)
Diabetes mellitus 33 (27) 7 (21)
Ischemic heart disease 53/122 (43) 3 (6) (P  .013)
Cerebrovascular disease 21/122 (17) 1 (5)
Atrial fibrillation 27/122 (22) 3 (11)
Medication
Platelet aggregation
inhibitor
87/119 (73) 14 (16)
Warfarin 26/119 (22) 3 (12)
Disease specifics
Acute critical lower
limb ischemia
88/119 (74) 12 (14)
Synthetic graft
occlusion
82/122 (67) 9 (11) (P  .092) 27
Supra-inguinal prox
anastomosis
26/121 (21) 2 (8)
Graft stenosis, any 49/121 (4) 7 (14)
Adjunctive
intervention
87/121 (72) 14 (16) 20/
Outcome
Major hemorrhage 16/121 (13) 3 (19)
Technical failure 18/123 (15) — 8
Major amputation 34/122 (28) —
P values .10 are denoted.123) was 69 years (SD 11.5 years; range, 27-91 years); 38% aere women. There was no significant difference in mean
ge between the genders (P  .45). Seven (5.7%) patients
ad history of graft occlusion for more than 14 days.
lmost three-quarters of patients suffered from hyperten-
ion, and just over two-thirds had a history of past or
ngoing smoking. A summary of the population character-
stics can be found in Table I (left-hand column).
Graft age, material, and anatomy. The median time
nterval between initial bypass graft placement and graft
cclusion was 39.5 months (range, 0.5-507 months). The
umber, anatomy, and vein/synthetic ratio of each specific
ypass graft are listed in Table II. Six patients had two
ccluded bypass grafts: femoral-femoral crossover femo-
opopliteal bypass below knee (n  4), femoral-femoral
rossover  femoropopliteal bypass above knee (n  1),
adverse outcome after thrombolysis for bypass graft
putation (%) Mortality (%)
Major amputation or
mortality (%)
122 (28) 57 (46) 65 (53)
/46 (35) 25 (53) 29 (62)
/25 (32) 19/26 (73) (P  .002) 19/26 (73) (P  .02)
25 (29) 43 (50) (P  .077) 48 (56)
/87 (31) 48 (55) (P  .005) 53 (60) (P  .013)
11 (33) 17 (52) 19 (58)
/52 (27) 28 (53) 30 (57)
/20 (25) 13/21 (62) 14/21 (67)
/26 (23) 16/27 (59) 16/27 (59)
/86 (27) 39 (45) 46 (53)
9 (35) 11 (42) 12 (46)
/87 (30) 47 (53) (P  .008) 51 (58) (P  .065)
(P  .043) 39 (48) 46 (56)
8 (31) 9 (35) 12 (46)
14 (29) 21 (43) 25 (51)
3) (P  .098) 40 (46) 45 (52)
6 (38) 11 (69) (P  .053) 12 (75) (P  .057)
(P  .089) 10 (56) 11 (61)
— 27 (79) (P  .001) —
able II. Graft anatomy and material among 121
atients undergoing thrombolysis for occluded bypasses
ypass graft anatomy Patients (%) Vein:Synthetic
ortobifemoral bypass 25 (21) 0:25
emoral-femoral crossover bypass 9 (7) 0:9
emoropopliteal bypass above knee 25 (21) 4:21
emoropopliteal bypass below knee 27 (22) 13:14
emorodistal bypass 29 (24) 23:6
wo bypass grafts 6 (4) 0:6-term
jor am
34/
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information on graft anatomy. The majority of the grafts,
82 of 122 (67%), were synthetic (polytetrafluoroethylene,
Dacron, or composite). All patients with occluded aortobi-
femoral, femoral-femoral crossover, or two occluded by-
pass grafts were of synthetic material.
Symptoms preceding thrombolytic treatment. Most
patients presented with acute critical leg ischemia (Ruther-
ford class 4 and above; 74% [89/120]), whereas 24%
(29/120) complained of new-onset intermittent claudica-
tion (Rutherford classes 1–3). Two patients were asymp-
tomatic (Rutherford class 0, discovered on postoperative
ultrasound examination of the graft).
Findings at angiography contributing to bypass
graft occlusion. The median duration of thrombolysis
was 19 hours (range, 1-51 hours). No underlying lesions
contributing to the graft occlusions were seen in 28 out of
121 (23.1%) documented cases. Graft-related lesions were
seen in 52 (43.0%) patients, and these occlusions were
considered to be caused by stenosis of the proximal anas-
tomosis (n  10) and the distal anastomosis (n  29),
stenosis of the graft (n 11), and a too-long graft prone to
kinking (n 2). In- and outflow stenosis and poor runoff in
the native arterial system were seen in 15 (12%), 33 (27%),
and 9 (7%) patients, respectively. Twenty-five patients had
more than one significant lesion.
Complications to thrombolysis. Fatal myocardial in-
farction occurred in three patients (2.4%). There were two
patients with stroke (1.6%), of which one was fatal. Both
strokes were hemorrhagic. Major hemorrhage occurred in
13.2% (16/121) of the patients. There was no relation
between the total given dose of actilyse and major hemor-
rhage (P .21). Age (P .52) and graft material (P .19)
were not associated with major hemorrhage.
Adjunctive interventions. In 29% (35/121) of cases,
no adjunctive interventions were required, whereas 26 pa-
tients (21%) underwent open surgery, 47 (39%) endovas-
cular intervention, and 13 (11%) underwent a hybrid pro-
cedure. There was no difference in the requirement of
additional interventions between vein and synthetic grafts
(P  .59).
Factors associated with technical failure of throm-
bolytic therapy. Technical failure of thrombolysis oc-
curred in 18 patients (15%). Patients with ischemic heart
disease had a decreased rate of technical failure (P  .013;
Table I, second column). There was a trend toward in-
creased likelihood of technical failure of thrombolytic treat-
ment of vein grafts compared with synthetic grafts (P 
.092). Themedian time interval between initial bypass graft
placement and graft occlusion was 45 months (range, 0.5-
507 months) among those with successful thrombolysis
compared with 10 months (range, 1.0-120 months)
among those with failure of thrombolysis (P .014). Total
dose of actilyse given was not associated with technical
failure rates (P .18). There was no difference in technical
failure between grafts with suprainguinal proximal anasto-
moses and infrainguinal bypass grafts (P  .24). When
entering ischemic heart disease, age of the graft, and graft saterial in a binary logistic regression model, ischemic
eart disease remained as an independent factor for techni-
al success of thrombolysis (P  .04; OR 4.0 95% CI
1.1-15.1]). There was a trend toward older grafts being
ssociated with a higher rate of successful thrombolysis
P  .089). Patients with ischemic heart disease were not
ore often on clopidogrel, warfarin, or combination of
arfarin and antithrombotic treatment in comparison with
atients without ischemic heart disease (P  .51).
Factors associated with major amputation during
ollow-up. Mean follow-up was 38 months (range, 0-119
onths). The amputation rate was 11.4% (14/123) at 1
onth and 25.4% (31/122) at 1 year. Technical failure was
ighly correlated with amputation at 1 month (P  .001;
 .29). In total, 34 patients (28%) underwent major
mputation during the follow-up period. Higher age was
ssociated with major amputation (P  .008). Synthetic
raft material was associated with an increased amputation
ate (P  .043). There was no difference in amputation
ates between grafts with suprainguinal proximal anasto-
oses and infrainguinal bypass grafts (P  .67). Time
etween graft placement and occlusion was not associated
ith amputation (P  .53). There was a trend that under-
oing an adjunctive intervention was associated with a
ecreased amputation rate (Table I, third column). The
mputation rate for patients who did not undergo any
dditional interventions was 37%. When entering technical
ailure, age, vein or synthetic graft material, and perfor-
ance of any additional endovascular or surgical interven-
ions in a Cox regressionmodel, technical failure (P .031;
R 2.58 [1.09-6.08]), higher age (P  .004; HR 1.060,
5% CI [1.019-1.103]) and synthetic graft as opposed to
ein graft (P  .050; HR 2.63 [1.00-6.92]) remained as
ndependent factors associated with amputation.
Factors associated with mortality. The mortality
ate was 6.5% (8/123) and 13% (16/123) at 1 and 12
onths, respectively. When entering age, smoking, hyper-
ension, presence of acute limb ischemia, major hemor-
hage, and major amputation (see Table I, fourth column)
n a Cox regression model, higher age (P  .003; HR
.050, 95% CI [1.017-1.084]), presence of acute limb
schemia (P  .006; HR 3.22, 95% CI [1.39-7.48]), and
ajor amputation (P  .001; HR 2.63, 95% CI [1.41-
.90]), remained as independent factors associated with
ortality.
Amputation-free-survival after thrombolysis. The
mputation-free survival rate was 89% and 75% at 1 and 12
onths, respectively. None of the six patients receiving
hrombolysis for two occluded bypass grafts at the same
ime had their leg preserved, and all died during follow-up.
hen entering age, hypertension, acute limb ischemia, and
ajor hemorrhage (see Table I, fifth column) in a Cox
egressionmodel, higher age (P .001;HR 1.060, 95%CI
1.031-1.090]) and acute limb ischemia (P  .007; HR
.40, 95% CI [1.26-4.56]) remained as independent ad-
erse factors associated with amputation-free survival. The
mputation-free survival curves in patients with vein and
ynthetic bypass grafts are seen in the Fig.
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This series of consecutive thrombolysis of occluded
lower limb bypass grafts from two large Swedish vascular
centers represents one of the largest published. The tech-
nical success rate was high, whereas the amputation rate
increased to 25% at 1 year, which is in line with a recent
published study from another tertiary vascular center.7
Unexpectedly, the present study showed that ischemic
heart disease was a factor for technical success of thrombol-
ysis. This finding was not related to group differences in
antithrombotic or anticoagulation therapy or type of graft.
Technical failure, higher age, and synthetic graft were
factors associated with major amputation during follow-up.
Some authors advocate a more selective approach toward
thrombolysis for occluded bypass grafts due to poor mid-
term results with high reocclusion rate and the inherent risk
of hemorrhagic complications.8
One advantage with successful thrombolysis over the
open surgical technique is that it allows an accurate assess-
ment of the vascular tree and underlying causes contribut-
ing to bypass graft failure. Indeed, the majority of patients
in this study underwent subsequent correction of an under-
lying stenosis within the graft and/or of an in- or outflow
stenosis. In addition, thrombolysis has been reported to
result in more patent outflow vessels compared with surgi-
cal thrombectomy.9 Pursuing endovascular treatment has
Legs at risk:          39 (0.06)          32 (0.06)           23 (0.06)        
                               82 (0.04)          58 (0.05)            50 (0.05)       
Fig. Amputation-free survival after thrombolysis for b
Numbers below time axis denote limbs at risk in each g
proportion leg surviving at end of interval is within pareother advantages in this group of patients, who are often slderly with multiple comorbidities. Surgical trauma is re-
uced, minimizing the inflammatory response, need for
nalgesic medication, and immobilization, and there is also
reduced risk of postoperative infection. An older prospec-
ive randomized trial of surgery versus thrombolysis for
ccluded lower extremity bypass grafts showed that pa-
ients with acute limb ischemia with a duration of graft
cclusion of 14 days, randomized to thrombolysis, had
ower short-term amputation rates compared to surgical
atients.10 However, in the aforementioned study, it was
ot possible to place a thrombolytic catheter in a high
roportion (39%) of patients who subsequently required
urgical revascularization. Since then, major advances in
ndovascular treatment have been achieved, including in-
reasing skills and material knowledge by the intervention-
sts and technical development of catheters and other en-
ovascular tools.11
One should bear in mind that the selected patients in
his and probably in other studies on thrombolysis of bypass
rafts seem to be composed by grafts with an already
hortened life span. Synthetic grafts appeared to have a
omewhat increased likelihood of technically successful
hrombolysis compared with vein grafts, but on the other
and they exhibited an increased risk of amputation during
ollow-up. The latter finding has also been noted in previ-
us studies.10,12 The assumed higher late occlusion rate of
0.06)            12 (0.06)           4 (0.06)    vein graft
0.06)            32 (0.06)          22 (0.07)   synthetic graft
P=0.10 
graft occlusion in patients with lower limb ischemia.
at respective time points. Standard error of cumulative
es. The tick marks indicate censored data.    16 (
     41 (
ypass
roupynthetic grafts with subsequent higher amputation rate
R1
1
1
1
1
1
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previous vascular surgery in the same limb and ligation of
important collateral arteries, higher likelihood of graft in-
fection after thrombolysis, inferior prerequisites for durable
bypass surgery options, and a conduit with inferior elasticity
and accommodation properties.13 There may be a rationale
for repeat ultrasound scanning surveillance of these syn-
thetic bypass grafts for estimation of graft flow and stenosis
development. Patients with grafts exhibiting low flow may
also benefit from warfarin therapy.14 A worse outcome was
observed among those six patients that had two occluded
synthetic grafts simultaneously in the present study. Such
high-risk conduits may benefit from improved anticoagu-
lation therapy. Conrad et al, on the other hand, suggested
repeat operation with a completely new bypass graft as a
more appropriate option due to poor short-term results of
thrombolysis of occluded prosthetic grafts.15 In contrast
with previous findings,16 this patient series did not exhibit
an increased risk of major hemorrhagic complications after
thrombolysis of synthetic grafts.
The limitations of the present study are attributed to its
retrospective design as well as absence of complete patency
data. Furthermore, it was not possible to obtain accurate
assessment of symptomduration prior to thrombolysis, which
may be important for overall outcome analysis since throm-
bosed vein bypass grafts are more resistant to thrombus re-
moval compared with synthetic grafts as time progresses.
In conclusion, our findings support the use of throm-
bolysis in the treatment of acute bypass graft occlusion in
the lower limb given its acceptable short- and long-term
amputation-free survival rates.
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